01/19/23 7:45 AMNasdaq, NYSE : JAZZ, ZYME clinical trialJazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaJazz Pharmaceuticals plc and Zymeworks Inc. today announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with...RHEA-AIneutral
01/03/23 7:30 AMNasdaq : JAZZ conferencesJazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41 st Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the companyRHEA-AIneutral
12/21/22 7:30 AMNasdaq : JAZZ, ZYME partnershipJazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for ZanidatamabJazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option toRHEA-AIvery positive
12/05/22 8:00 AMNasdaq : JAZZ Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset EpilepsiesReal-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey presented at the 2022 American Epilepsy Society Annual Meeting expands evidence behind Epidiolex treatment in adult and pediatric patientsCaregivers of Lennox-Gastaut Syndrome and Dravet SyndromeRHEA-AIneutral
11/28/22 8:09 AMNasdaq : JAZZ conferencesJazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual MeetingJazz Pharmaceuticals plc (Nasdaq: JAZZ)RHEA-AIneutral
11/18/22 1:00 PMNasdaq : JAZZ fda approvalJazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced theRHEA-AIvery positive
11/14/22 9:00 AMNasdaq : JAZZ STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENINGStand Up To Cancer ® (SU2C) announced today the launch of a new public service announcement (PSA) campaign in partnership with Jazz Pharmaceuticals plc. The PSA aims to raise awareness in Black and Hispanic communities about small cell lung cancer andRHEA-AIneutral
11/09/22 4:05 PMNasdaq : JAZZ earningsJazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-pointJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total revenue guidance. "Our execution across our business continues to chart a clear path to delivering on Vision 2025. WeRHEA-AIpositive
11/03/22 10:43 AMNasdaq : JAZZ conferencesJazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology ResearchJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13RHEA-AIneutral
11/01/22 4:15 PMNasdaq : JAZZ conferencesJazz Pharmaceuticals to Participate in Upcoming November Investor ConferencesJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences:Jefferies London Healthcare Conference on Tuesday, November 15, 2022The presentation is scheduled for 5:20 a.m. ET / 10:20RHEA-AIneutral